MediWound Ltd. (MDWD) shareholders
Close on Nov 16, 2026Market cap $173.92MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Access Industries Holdings LLC Joint filing with Access Industries, LLC (11.56%), Access Industries Management, LLC (11.56%) and 4 more | 1,481,521 | 11.56% | 13D (active) amendment | Sep 30, 2025 |
| HOLD Alapkezelo Zrt. | 1,348,323 | 10.40% | 13G (passive) amendment | Aug 27, 2026 |
| / . Israel Biotech Fund II, L.P. Joint filing with / . Israel Biotech Fund GP Partners II, L.P. (10.40%), / . I.B.F Management Ltd. (10.40%) | 959,652 | 10.40% | 13G (passive) amendment | Dec 31, 2023 |
| / . Deep Insight Management Ltd. Joint filing with / . Deep Insight Limited Partnership (10.40%), / . Deep Insight Fund GP Limited Partnership (10.40%) and 3 more | 959,652 | 10.40% | 13G (passive) amendment | Dec 31, 2023 |
| Aharon Gil Joint filing with Rosalind Advisors, Inc. (7.00%), Salamon Steven A J (7.00%) and 1 more | 912,319 | 7.00% | 13G (passive) amendment | Dec 31, 2025 |
| Patricia Industries AB Joint filing with Mölnlycke Health Care AB (8.10%), MHC Sweden AB (8.10%) and 4 more | 872,093 | 8.10% | 13D (active) | Jul 17, 2024 |
| Salamon Steven A J Joint filing with Rosalind Advisors, Inc. (7.20%), Aharon Gil (7.20%) and 1 more | 791,315 | 7.20% | 13G (passive) amendment | Dec 31, 2024 |
| Dov Yelin Joint filing with Yelin Lapidot Holdings Management Ltd. (5.95%), Yair Lapidot (5.95%) | 763,069 | 5.95% | 13G (passive) amendment | Dec 31, 2025 |
| T. Rowe Price Associates, Inc. | 641,075 | 5.00% | 13G (passive) amendment | Jun 30, 2026 |
| Rosalind Advisors, Inc. Joint filing with Salamon Steven A J (5.20%), Aharon Gil (5.20%) and 1 more | 570,326 | 5.20% | 13G (passive) amendment | Jun 30, 2025 |
| 1,481,521 12 Check Box If The Aggregate Amount In Row (11) Excludes Certain Shares: ☐ 13 Percent Of Class Represented By Amount In Row (11): 13.8%* 14 Type Of Joint filing with 1,172,710 12 Check Box If The Aggregate Amount In Row (11) Excludes Certain Shares: ☒ 13 Percent Of Class Represented By Amount In Row (11): 10.92%* 14 Type Of (10.92%) | – | 13.80% | 13D (active) amendment | Jul 17, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MDWD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Investor Ab | 872,093 | 6.79% | $12.82M | – | 0.09% |
| Yelin Lapidot Holdings Management Ltd. | 758,169 | 5.91% | $11.15M | −4,648 | 2.11% |
| Rosalind Advisors, Inc. | 749,054 | 5.84% | $11.01M | – | 4.09% |
| Price T Rowe Associates Inc /Md/ | 641,075 | 4.99% | $9.43M | −68,772 | 0.00% |
| BlackRock, Inc. | 525,929 | 4.10% | $7.73M | +80,095 | 0.00% |
| Sphera Funds Management Ltd. | 273,192 | 2.13% | $4.02M | – | 0.52% |
| Silverberg Bernstein Capital Management LLC | 228,137 | 1.78% | $3.35M | +28,132 | 1.28% |
| State Street Corp | 168,669 | 1.31% | $2.48M | +24,899 | 0.00% |
| UBS Group AG | 155,922 | 1.21% | $2.29M | −3,869 | 0.00% |
| Geode Capital Management, LLC | 141,041 | 1.10% | $2.07M | +19,083 | 0.00% |
| Point72 Asset Management, L.P. | 129,248 | 1.01% | $1.90M | −46,231 | 0.00% |
| ARK Investment Management LLC | 126,576 | 0.99% | $1.86M | −3,385 | 0.01% |
| Northern Trust Corp | 112,191 | 0.87% | $1.65M | −9,585 | 0.00% |
| DAFNA Capital Management LLC | 94,405 | 0.74% | $1.39M | – | 0.26% |
| Morgan Stanley | 88,660 | 0.69% | $1.30M | +187 | 0.00% |
| Clal Insurance Enterprises Holdings Ltd | 71,000 | 0.55% | $1.04M | – | 0.00% |
| Vanguard Portfolio Management LLC | 70,143 | 0.55% | $1.03M | +12,596 | 0.00% |
| Sargent Investment Group, LLC | 62,481 | 0.49% | $918.47K | +3,000 | 0.11% |
| Citadel Advisors LLC | 58,496 | 0.46% | $859.89K | −744 | 0.00% |
| Aqr Capital Management LLC | 50,357 | 0.39% | $740.25K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 79 | 6M | 45.3% | 15 / 29 | 19 / 10 | 0M | 1M |
| Q1 2026 | 76 | 6M | 47.1% | 17 / 27 | 18 / 17 | 1M | 0M |
| Q4 2025 | 78 | 6M | 48.4% | 15 / 31 | 17 / 10 | 1M | 0M |
| Q3 2025 | 76 | 6M | 45.0% | 18 / 30 | 14 / 10 | 2M | 0M |
| Q2 2025 | 68 | 4M | 34.6% | 9 / 19 | 25 / 5 | 0M | 0M |
| Q1 2025 | 64 | 4M | 33.4% | 10 / 25 | 18 / 9 | 0M | 0M |
| Q4 2024 | 64 | 4M | 34.5% | 7 / 25 | 13 / 5 | 0M | 0M |
| Q3 2024 | 63 | 4M | 32.8% | 22 / 16 | 17 / 3 | 2M | 0M |
| Q2 2024 | 45 | 3M | 21.1% | 19 / 10 | 9 / 5 | 1M | 0M |
| Q1 2024 | 31 | 2M | 17.7% | 13 / 11 | 5 / 4 | 1M | 1M |
| Q4 2023 | 22 | 3M | 19.6% | 7 / 4 | 7 / 3 | 1M | 0M |
| Q3 2023 | 18 | 2M | 15.9% | 1 / 3 | 9 / 2 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ofer Gonen | Chief Executive Officer | 66,019 | 0.51% | Nov 12, 2026 |
| Shmuel Hess | COO & Chief Commercial Officer | 0 | – | Aug 28, 2026 |
| Ety Klinger | Chief Medical Officer | 1,500 | 0.01% | Mar 18, 2026 |
| Yaron Meyer | EVP, GC & Corp. Secretary | 2,357 | 0.02% | Mar 18, 2026 |
| Yaakov Aya Ben | VP Clinical & Reg. Affairs | 125 | 0.00% | Mar 18, 2026 |
| Kalfon Hana Luxenburg | Chief Financial Officer | 3,000 | 0.02% | Mar 18, 2026 |
| Nachum Shamir | Director | 72,151 | 0.56% | Nov 12, 2026 |
| David Morton Fox | Director | 28,817 | 0.22% | Nov 12, 2026 |
| Samuel Rubinstein | Director | 750 | 0.01% | Sep 2, 2026 |
| Vickie Rae Driver | Director | 750 | 0.01% | Mar 25, 2026 |
| Stephen T. Wills | Director | 750 | 0.01% | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ofer Gonen Chief Executive Officer | Nov 11, 2026 | Option exercise | +8,168 | $13.47 | $110.06K | 66,019 |
| Nachum Shamir Director | Nov 10, 2026 | Option exercise | +16,336 | $13.47 | $220.13K | 72,151 |
| David Morton Fox Director | Nov 10, 2026 | Option exercise | +6,534 | $13.47 | $88.05K | 28,817 |
| Samuel Rubinstein Director | Sep 1, 2026 | Sale | −525 | $12.72 | $6.68K | 0 |
| Samuel Rubinstein Director | Sep 1, 2026 | Buy | +525 | $12.62 | $6.63K | 525 |
| Shmuel Hess COO & Chief Commercial Officer | Aug 27, 2026 | Sale | −1,979 | $12.72 | $25.17K | 0 |
| Shmuel Hess COO & Chief Commercial Officer | Aug 27, 2026 | Sale | −1,979 | $13.13 | $25.98K | 0 |
| Shmuel Hess COO & Chief Commercial Officer | Aug 26, 2026 | Sale | −1,865 | $13.00 | $24.25K | 0 |
| Nachum Shamir Director | Jun 3, 2026 | Buy | +5,825 | $14.00 | $81.55K | 55,815 |
| Nachum Shamir Director | Jun 3, 2026 | Buy | +175 | $13.98 | $2.45K | 49,990 |
| David Morton Fox Director | Jun 1, 2026 | Buy | +1,797 | $14.00 | $25.16K | 22,283 |
| David Morton Fox Director | Jun 1, 2026 | Buy | +10 | $14.23 | $142 | 20,486 |
| David Morton Fox Director | Jun 1, 2026 | Buy | +1,730 | $14.23 | $24.62K | 20,476 |
| Samuel Rubinstein Director | May 29, 2026 | Buy | +150 | $14.33 | $2.15K | 2,993 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of MediWound's stock actually held short. Settlement fails (shares not delivered on time) peaked at 37,471 shares on Aug 28, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Shmulik Hess Officer | Aug 28, 2026 | 3,958 | $50.27K | Aug 27, 2026 | Shares acquired upon exercise of employee stock options |
| Shmuel Hess Officer | Dec 3, 2025 | 3,693 | $63.56K | Dec 2, 2025 | Employee Stock Option Plan |
See a number that looks wrong?